{"cell_type":{"9b683e4e":"code","d5a5e6a4":"code","38f84098":"code","82038e64":"code","f9351bf2":"code","9176ece3":"code","ae247e4d":"code","771307b7":"code","e9c92cc3":"code","dfbe62ce":"code","f4efa9a3":"code","bcc448d7":"code","0a46c0d2":"code","3a91659d":"code","01eeef75":"code","9d0361e8":"code","ef7f2122":"code","5691c62d":"code","3b64751f":"code","50763c96":"code","e3c5d519":"code","dfab60fd":"markdown","bd7b3447":"markdown","bc338e8c":"markdown","f624812f":"markdown","6eac4279":"markdown","cca7db5a":"markdown","7ee8cdf2":"markdown","352d4ad9":"markdown","cd200050":"markdown","52197cb4":"markdown","28906e2a":"markdown","d7b3ff81":"markdown","be663859":"markdown"},"source":{"9b683e4e":"from IPython.display import Markdown, display","d5a5e6a4":"#Codes by Akshit Bhalla https:\/\/www.kaggle.com\/bhallaakshit\/who-are-they-a-comprehensive-analysis\n\ndef content(text):\n    \"\"\" This function allows you to output content \"\"\"\n    my_response = \"<div style= 'background-color:rgb(247, 247, 247); border:1px solid rgb(207,207,207); border-color:rgb(107,107,107); padding: 10px'> \\\n    <span style='color: black;  font-family: medium-content-serif-font, Georgia, Cambria, 'Times New Roman', Times, serif; \\\n    font-weight: 400; letter-spacing: -0.004em; line-height: 1.58; '>\"+ text + \"<\/span><\/div>\"\n    display(Markdown(my_response))","38f84098":"content(\n    \"Fiocruz and the Murdoch Children\u2019s Research Institute, in Australia, will begin testing the BCG \" +\n    \"vaccine on healthcare professionals, to verify the protection of the immunizer against Covid-19 as well.\" +\n    \"The trial, which was initially expected to be carried out only in the state of Mato Grosso do Sul, will\" +\n    \" be expanded to the state of Rio de Janeiro. \" + \"\\n\\n\" +\n    \"The research was approved by the National Committee of Ethics in Research (Conep) and \" +\n    \"is coordinated in Brazil by Fiocruz researchers Julio Croda and Margareth Dalcolmo.\" +\n    \"https:\/\/portal.fiocruz.br\/en\/news\/fiocruz-will-be-testing-bcg-vaccine-prevention-covid-19-brazil\"\n)","82038e64":"# This Python 3 environment comes with many helpful analytics libraries installed\n# It is defined by the kaggle\/python Docker image: https:\/\/github.com\/kaggle\/docker-python\n# For example, here's several helpful packages to load\n\nimport numpy as np # linear algebra\nimport pandas as pd # data processing, CSV file I\/O (e.g. pd.read_csv)\nimport matplotlib.pyplot as plt\nimport seaborn as sns\nimport warnings\nimport math\nimport plotly.express as px\nimport plotly.graph_objects as go\n\nwarnings.filterwarnings('ignore')\nsns.set_palette('Set2')\nsns.set_style('darkgrid')\n\n# Input data files are available in the read-only \"..\/input\/\" directory\n# For example, running this (by clicking run or pressing Shift+Enter) will list all files under the input directory\n\nimport os\nfor dirname, _, filenames in os.walk('\/kaggle\/input'):\n    for filename in filenames:\n        print(os.path.join(dirname, filename))\n\n# You can write up to 20GB to the current directory (\/kaggle\/working\/) that gets preserved as output when you create a version using \"Save & Run All\" \n# You can also write temporary files to \/kaggle\/temp\/, but they won't be saved outside of the current session","f9351bf2":"content(\n    \"About 3,000 healthcare professionals in the country, who have not had Covid-19, will be vaccinated.\" +\n    \"The study will be funded by the Bill and Melinda Gates Foundation. Those approved for the study will \" +\n    \"receive the Danish BCG strain. 'We will be following these people for up to a year, during which interim  \" +\n    \"protection analysis will be made, that is, intermediary evaluations recommended for long-term studies'. \" + \"\\n\\n\" +\n    \"The clinical trial is in its phase 3 already, the stage where a significant number of people are tested.\"  +\n    \"Those people, on a weekly basis, will have to inform whether they experienced Covid-19 symptoms.\" +\n    \"https:\/\/portal.fiocruz.br\/en\/news\/fiocruz-will-be-testing-bcg-vaccine-prevention-covid-19-brazil\"\n)","9176ece3":"df = pd.read_csv('..\/input\/conditions-contributing-to-deaths-covid19\/NVSS_Provisional_COVID-19_Deaths_by_Place_of_Death_and_Age.csv', encoding='utf8')\npd.set_option('display.max_columns', None)\ndf.head()","ae247e4d":"content(\n    \"According to Croda this is a quantitative research that is in its last stage, when it is evaluated \" +\n    \"whether the BCG vaccine  is effective or not against Covid-19.\u201d In addition to Brazil, Australia, Spain, and \" +\n    \"the United Kingdom are also part of the research through the University of Melbourne, with the support of \" +\n    \"the World Health Organization (WHO). The Australian researchers based  themselves on existing studies that show \" +\n    \"that the BCG vaccine is efficient against other viral respiratory infections.\" +\"\\n\\n\" +\n    \"https:\/\/portal.fiocruz.br\/en\/news\/fiocruz-will-be-testing-bcg-vaccine-prevention-covid-19-brazil\"\n    \n)","771307b7":"df.isnull().sum()","e9c92cc3":"covdeaths = df.loc[1:, \"COVID-19 Deaths\"].value_counts()\ncategories = list(covdeaths.keys())\npalette = sns.color_palette(\"Set2\", len(categories)) \ncolors1 = {k:v for k,v in zip(categories, palette)}\ncolors2 = {k:v for k,v in zip(categories[:2] + [\"COVID-19 Deaths\"], palette[:2] + [(1, 0, 0)])}\ncolors3 = {k:v for k,v in zip(categories[2:], palette[2:])}","dfbe62ce":"content(\n    \"It is important to highlight that we still do not have proof that BCG is effective against Covid-19 \" +\n    \"or how long it keeps the body immune against other respiratory diseases. This means people should \" +\n    \"not take the vaccine in the belief it can prevent Covid-19.\" +\n    \"Available in the Brazilian Public Health System, the BCG vaccine has been compulsory for newborns in Brazil since 1976. \" +\"\\n\\n\"+\n    \"The vaccine protects children against the most serious forms of tuberculosis.\" +     \n    \"https:\/\/portal.fiocruz.br\/en\/news\/fiocruz-will-be-testing-bcg-vaccine-prevention-covid-19-brazil\"\n)","f4efa9a3":"temp = df.loc[1:, [\"Age group\", \"COVID-19 Deaths\"]]\n\n#temp = temp.rename(columns = {\n #   \"Q1\": \"age\",\n  #  \"Q2\": \"gender\"\n#})\n\ndf1 = temp.pivot_table(\n    index = \"Age group\", \n    columns = \"COVID-19 Deaths\", \n    aggfunc = {\n        \"COVID-19 Deaths\": \"count\"\n    },\n    fill_value = 0\n)\n\ndf1.columns = df1.columns.droplevel(0)\ndf1.columns.name = \"COVID-19 Deaths\"\n\ndf1[\"COVID-19 Deaths\"] = df1[categories[2]] + df1[categories[3]] + df1[categories[4]]\n\ndf1.drop(columns = categories[2:]).plot(\n    kind = 'bar', \n    stacked = True, \n    color = colors2\n)\nplt.xlabel(\"Age Group\")\nplt.ylabel(\"Count\")\nplt.title(\"COVID-19 Deaths by Age Group\")\nplt.show()","bcc448d7":"content(\n    \"Based on the capacity of BCG to reduce the incidence of respiratory tract infections in children and adults;\" +\n    \"exert antiviral effects in experimental models; and  reduce viremia in an experimental human model of viral\" +\n    \"infection, we hypothesize that BCG vaccination may induce (partial) protection against susceptibility to and\/or severity \" +\n    \"of SARS-CoV-2 infection.\" + \"\\n\\n\" +\n    \"This study will evaluate the efficacy of BCG to reduce risk of infection by SARS-CoV-2 and mitigate COVID-19 disease\" +\n    \" severity in at risk health care providers.\"\n    \"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04632537\"\n)","0a46c0d2":"sns.clustermap(\n    df1,\n    annot = True,\n    cmap = \"YlGnBu\",\n    fmt = \".2f\",\n    figsize = (7, 7)\n)\nplt.title(\"Covid-19 Deaths by Age\")\nplt.show()","3a91659d":"content(\n    \"This study is a multi-center, prospective, double-blind, randomized placebo-controlled trial to assess the efficacy\" +\n    \"of intradermal TICE BCG,  BCG LIVE or placebo vaccine, in reducing the incidence of infection of SARS-CoV2 and severity\" +\n    \"of COVID-19 disease. This study proposes to examine BCG-induced nonspecific trained immunity to provide protection from SARS-CoV2 \" +\n    \"among health care workers who are likely to care for patients with COVID-19 illness, 18-64 years of age.\" + \"\\n\\n\" +\n    \"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04632537\" \n    \n)","01eeef75":"px.treemap(df.groupby(by='Age group').sum().reset_index(), path=['Age group'], labels='Age group', \n           values='COVID-19 Deaths', title='COVID-19 Deaths by Age Group')","9d0361e8":"fig = px.treemap(df.groupby(by='Place of Death').sum().reset_index(), path=['Place of Death'], labels='Place of Death', \n           values='COVID-19 Deaths',color='COVID-19 Deaths', color_continuous_scale='Greens', title='COVID-19 Deaths by Place of Death ')\nfig.show()","ef7f2122":"content(\n    \"HIGHLIGHTS.\" + \"\\n\\n\" +\n    \"Recent BCG vaccination is safe during the COVID-19 pandemic.\" + \"\\n\\n\" +\n    \"BCG vaccination is not associated with symptoms of hyperinflammation.\" + \"\\n\\n\" +\n    \"BCG might be associated with reduced incidence of sickness and extreme fatigue.\" + \"\\n\\n\" +\n    \"Randomized trials of BCG vaccination for the prevention of COVID-19 are warranted.\" +\n    \"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379120300938\"\n    \n)","5691c62d":"fig = px.pie(df, values='COVID-19 Deaths', names='Age group', color_discrete_sequence=px.colors.sequential.RdBu, title='Covid-19 Deaths by Age Group')\nfig.show()","3b64751f":"#Codes by Huynh Dong Nguyen https:\/\/www.kaggle.com\/winternguyen\/covid-19-who-should-get-vaccine-first\/notebook\n\nfig = go.Figure(data=[go.Pie(labels=df['Place of Death'], values=df['COVID-19 Deaths'], hole=.3)])\nfig.update_layout(legend=dict(orientation=\"h\", title = \"COVID-19 Deaths by Place of Death\",\n    yanchor=\"bottom\",y=1.02,xanchor=\"right\",x=1))\nfig.show()","50763c96":"#Codes by Huynh Dong Nguyen https:\/\/www.kaggle.com\/winternguyen\/covid-19-who-should-get-vaccine-first\/notebook\n\nyprop = 'Total Deaths'\nxprop = 'COVID-19 Deaths'\nh= 'Age group'\nfig=px.scatter(df, x=xprop, y=yprop, color=h, marginal_y=\"violin\", marginal_x=\"box\", trendline=\"ols\", template=\"simple_white\")\nfig.update_layout(legend=dict(orientation=\"h\",yanchor=\"bottom\",y=1.02,xanchor=\"right\",x=1))\nfig.show()","e3c5d519":"#Code by Olga Belitskaya https:\/\/www.kaggle.com\/olgabelitskaya\/sequential-data\/comments\nfrom IPython.display import display,HTML\nc1,c2,f1,f2,fs1,fs2=\\\n'#eb3434','#eb3446','Akronim','Smokum',30,15\ndef dhtml(string,fontcolor=c1,font=f1,fontsize=fs1):\n    display(HTML(\"\"\"<style>\n    @import 'https:\/\/fonts.googleapis.com\/css?family=\"\"\"\\\n    +font+\"\"\"&effect=3d-float';<\/style>\n    <h1 class='font-effect-3d-float' style='font-family:\"\"\"+\\\n    font+\"\"\"; color:\"\"\"+fontcolor+\"\"\"; font-size:\"\"\"+\\\n    str(fontsize)+\"\"\"px;'>%s<\/h1>\"\"\"%string))\n    \n    \ndhtml('Be patient. Mar\u00edlia Prata, @mpwolke was Here' )","dfab60fd":"<font color=\"#EC7063\">Sponsors and Collaborators<\/font>\n\nHenry M. Jackson Foundation for the Advancement of Military Medicine\n\nHarvard Medical School\n\nUniformed Services University of the Health Sciences\n\nUnited States Department of Defense\n\nImmunization HealthCare Division, Defense Health Agency\n\n<font color=\"#EC7063\">Investigators<\/font>\n\n\nPrincipal Investigator:\tThomas G Oliver\t\n\nStudy Chair:\tNaomi E Aronson","bd7b3447":"![](https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2666379120300938-fx1.jpg)https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379120300938","bc338e8c":"### <b><mark style=\"background-color: #9B59B6\"><font color=\"white\">Detailed Description:<\/font><\/mark><\/b>\n\n<div class=\"alert alert-block alert-success\">\n   Up to 670 individuals will be screened to enroll 550 participants, resulting in 275 receiving BCG vaccine and 275 receiving placebo. \n    \n    \nThere are three phases in which research procedures will be completed: (1) initial screening for eligibility, consent, baseline testing; (2) enrollment, randomization, if pertains- prior to vaccination research blood draw for peripheral blood mononuclear cells (PBMC), and immunization with study vaccine (BCG or placebo); and (3) follow-up screening and testing.\n\nParticipants will be followed to assess whether infection with SARS-CoV-2 occurs:\n\nParticipants will complete intermittent surveys via an electronic system every 2 weeks to assess the presence of any flu-like symptom. Any positive response on the survey will trigger a nasopharyngeal swab to be collected to test for COVID-19 via rt-PCR.\n    \nAll participants, regardless of survey responses, will have serology (4mL SST tube) for COVID-19 tested at monthly intervals during the 6 month follow-up period or until a positive test result occurs.\n\nIf a participant completes the follow-up period and does not test positive for COVID disease, study participation is complete.\n\nIf a participant does test positive for COVID-19 disease at any point during follow-up, disease status will be ascertained for up to two months from the time of positive test or until an outcome is available through one of the following mechanisms:\n\n(1) an electronic survey if not admitted to the hospital, including questions about the number of days ill, daily fever, and other symptoms; or (2) if admitted to the hospital, ordinal outcomes for disease severity will be extracted from the hospital's medical records system for the 2 month period of highest acuity. Participants will have a final study visit after hospitalization when cleared for outpatient follow up.\n\nDuring the first 6 weeks of follow-up post vaccination, all participants will be asked about any adverse events; thereafter, participants will report vaccine-related and solicited adverse events (AE), as well as unsolicited AEs through the electronic survey.\n    \n \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT0463\n    \n\n<\/div>","f624812f":"<a id=\"1.1\"><\/a>\n<h3 style=\"background-color:skyblue;font-family:newtimeroman;font-size:200%;text-align:center\">BCG Vaccination to Prevent COVID-19 (NUEVA)<\/h3>","6eac4279":"<a id=\"1.1\"><\/a>\n<h3 style=\"background-color:skyblue;font-family:newtimeroman;font-size:200%;text-align:center\">Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG<\/h3>","cca7db5a":"\n<div class=\"alert alert-block alert-success\">\n    \n  BCG vaccination trials for reducing SARS-CoV-2 infection are underway, but concerns have been raised regarding the potential harm of strong innate immune responses.\n\n   To investigate the safety of BCG vaccination, the authors retrospectively assessed coronavirus disease 2019 (COVID-19) and related symptoms in three cohorts of healthy volunteers who either received BCG in the last 5 years or did not.\n\n   BCG vaccination is not associated with increased incidence of symptoms during the COVID-19 outbreak in the Netherlands. Their data suggested that BCG vaccination might be associated with a decrease in the incidence of sickness during the COVID-19 pandemic (adjusted odds ratio 0.58, p minor than 0.05), and lower incidence of extreme fatigue. \n\n  In conclusion, recent BCG vaccination is safe, and large randomized trials are needed to reveal if BCG reduces the incidence and\/or severity of SARS-CoV-2 infection.\n    \n  https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379120300938  \n    \n\n<\/div>\n\n","7ee8cdf2":"<a id=\"1.1\"><\/a>\n<h3 style=\"background-color:skyblue;font-family:newtimeroman;font-size:200%;text-align:center\">Fiocruz will be testing BCG vaccine for the prevention of Covid-19<\/h3>","352d4ad9":"#Codes by Akshit Bhalla https:\/\/www.kaggle.com\/bhallaakshit\/who-are-they-a-comprehensive-analysis","cd200050":"### <b><mark style=\"background-color: #9B59B6\"><font color=\"white\">Overview of the Study<\/font><\/mark><\/b>\n\nThe dataset consists of 430 adult volunteers of which 266 volunteers received the BCG vaccine in the last 5 years and 164 individuals did not receive the BCG vaccine (control group).\n\nInformation about disease and any symptoms between February 27th to April 30th 2020, as well as other metadata including recent travel history and previous contact with SARS-CoV-2 infected individuals were collected via two digital surveys that were sent to participants of the 300BCG, 500FG, and BCG-booster cohorts.\n\nParticipants that received a BCG vaccination before 2015 and participants from the BCG booster cohort that received a BCG vaccine between February 27th and April 30th were excluded from analysis.\n\nCirculating immune parameters were assessed in individuals from the 300BCG and 500FG cohorts.\n\nThe BCG-induced trained immunity response was assessed in the 300BCG cohort by comparing cytokine levels upon ex vivo stimulation of peripheral blood mononuclear cells (PBMCs) 3 months after BCG vaccination to the levels before vaccination.\n\nAnnotation: ResponseQ1 = response survey 1, containing information on disease and symptoms between February 27th to March 31st 2020; ResponseQ2 = response survey 2, containing information on disease and symptoms between April 1st to April 30th 2020. \nhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379120300938","52197cb4":"<a id=\"1.1\"><\/a>\n<h3 style=\"background-color:red;font-family:newtimeroman;font-size:200%;text-align:center\">\"Limitations of Study\n    \n    \nCaution is warranted in interpreting our findings: limitations include the retrospective nature of the study in two relatively small groups of volunteers, and the potential for selection bias.\n    \nFurthermore, a microbiological diagnosis was absent in the majority of the individuals, and the authors may have captured sickness and symptoms unrelated to COVID-19. For these reasons, the data in that study indicate that BCG vaccination is safe during the COVID-19 outbreak, but does not permit conclusions regarding a potential beneficial effect of BCG against SARS-CoV-2 infection.\n    \nWhether BCG has a protective effect specifically against COVID-19 needs to be investigated in future randomized clinical trials.\"<\/h3>\nhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379120300938","28906e2a":"Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study\n\nAuthors: Simone J.C.F.M.Moorlag, Rosanne C.van Deuren, Cornelis H.van Werkhoven, MartinJaeger, PriyaDebisarun,  EstherTaks, Vera P.Mourits, Valerie A.C.M.Koeken, L. Charlotte J.de Bree, Thijsten Doesschate, Maartje C.Cleophas,  SanneSmeekens, MarijeOosting, Frank L.van de Veerdonk, Leo A.B.Joosten, Jaapten Oever, Jos W.M.van der Meer, NigelCurtis, \u2026Mihai G.Netea\n\nCell Reports Medicine - Volume 1, Issue 5, 25 August 2020, 100073 - https:\/\/doi.org\/10.1016\/j.xcrm.2020.100073\n\n","d7b3ff81":"#Codes by Huynh Dong Nguyen https:\/\/www.kaggle.com\/winternguyen\/covid-19-who-should-get-vaccine-first\/notebook","be663859":"<font color=\"#EC7063\">BCG Vaccination Is Not Associated with Increased Disease or Severity of COVID-19-Related Symptoms<\/font>\n\n\n(A) Percentage of participants with reported positive COVID-19 diagnosis (diagnosis made by PCR\/physician based on clinical symptoms) in the BCG-vaccinated (n = 266) and control group (n = 164) (p = Fisher\u2019s exact test p value).\n\n(B) Percentage of SARS-CoV-2-related hospital admission in the BCG-vaccinated (n = 266) and control group (n = 164).\n\n(C) Percentage of self-reported sickness between February 27th and April 30th 2020 in the BCG-vaccinated (n = 266) and control group (n = 164) (p = chi-square test p value; adjp = logistic regression adjusted p value).\n\n(D) The average number of reported days of sickness in the BCG-vaccinated and control group (n = 106, p = Wilcoxon rank-sum test p value).\n\n(E) Percentage of individuals that reported any symptom in the BCG-vaccinated (n = 266) and control group (n = 164) (p = chi-square test p value).\n\n(F) Percentage of individuals that reported the indicated specific symptom between February 27th and April 30th 2020 in the BCG-vaccinated (n = 266) and control group (n = 164) (p = chi-square test p value).\n\n\n\n![](https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2666379120300938-gr2.jpg)https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379120300938"}}